Palisade Bio Stock (NASDAQ:PALI)

Forecast Ownership Financials Chart

Previous Close

$1.80

52W Range

$1.38 - $22.35

50D Avg

$2.65

200D Avg

$4.19

Market Cap

$5.01M

Avg Vol (3M)

$1.25M

Beta

1.33

Div Yield

PALI Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 30, 2007

Website

PALI Performance

PALI Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$250.00K	-	-
Operating Income	$-12.85M	$-15.72M	$-41.85M
Net Income	$-12.32M	$-12.80M	$-27.27M
EBITDA	$-12.84M	$-15.15M	$-44.28M
Basic EPS	$-27.01	$-14.54	$-146.46
Diluted EPS	$-27.01	$-14.54	$-145.87

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
PHIO	Phio Pharmaceuticals Corp.
IMMX	Immix Biopharma, Inc.
CYTO	Altamira Therapeutics Ltd.
ZURA	Zura Bio Limited
UNCY	Unicycive Therapeutics, Inc.
ENVB	Enveric Biosciences, Inc.